• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
N Engl J Med. Author manuscript; available in PMC Nov 10, 2010.
Published in final edited form as:
PMCID: PMC2978046
NIHMSID: NIHMS249960

Failure to Validate Association between 12p13 Variants and Ischemic Stroke

International Stroke Genetics Consortium and Wellcome Trust Case–Control Consortium 2

TO THE EDITOR: Recently published data from a meta-analysis of genomewide association studies showed that two common single-nucleotide polymorphisms (SNPs) near the NINJ2 and WNK1 genes on chromosome 12p13 were associated with ischemic and, in particular, atherothrombotic strokes.1 To validate these results, we conducted a meta-analysis in a combined sample of 8637 cases and 8733 controls of European ancestry, as well as one population-based genomewide cohort study of 278 ischemic strokes among 22,054 participants.

Both SNPs from the original report (rs12425791 and rs11833579) were tested for association with ischemic stroke, as well as incident stroke, recurrent stroke, and stroke subtypes (according to the Trial of Org 10172 in Acute Stroke Treatment [TOAST] criteria2). We also conducted similar analyses in cases and controls of African-American ancestry and in samples from Chinese and Pakistani subjects. Furthermore, we evaluated gene expression for NINJ2 and WNK1 in 132 cases with ischemic stroke and in 80 controls, as well as the association of the chromosome 12p13 variants with the risk of hemorrhagic stroke. Details regarding the study design and extended results are available in the Supplementary Appendix, available with the full text of this letter at NEJM.org.

We found no association between rs12425791 and ischemic stroke (odds ratio, 0.97; 95% confidence interval [CI], 0.91 to 1.04; P = 0.41) or between rs11833579 and ischemic stroke (odds ratio, 1.02; 95% CI, 0.95 to 1.10; P = 0.55) in persons of European ancestry (Fig. 1). We found no association between either of the SNPs and atherothrombotic stroke in 2235 cases (P>0.10) (Fig. 2) and no association between either of the SNPs and incident ischemic stroke, recurrent ischemic stroke, and ischemic stroke subtypes (P>0.10 for all comparisons). The power to detect an association at an effect size below the lower limit of the 95% confidence interval surrounding the original estimate exceeded 99% for ischemic as well as atherothrombotic stroke. We observed no differences in gene expression between cases and controls and no association between either of the SNPs and a risk of hemorrhagic stroke. Heterogeneity in meta-analyses of our studies was not significant (P>0.20 for heterogeneity, proportion of total variation in study estimates because of heterogeneity in the meta-analysis [I2] <20%),3 although we did identify significant heterogeneity in the original report’s meta-analyses for rs11833579 (P = 0.07 for heterogeneity, I2 = 56.1%) and rs12425791 (P = 0.15 for heterogeneity, I2 = 42.1%).1

Figure 1
Associations between Single-Nucleotide Polymorphisms (SNPs) and Ischemic Strokes in Persons of European Ancestry, According to Study
Figure 2
Associations between Single-Nucleotide Polymorphisms (SNPs) and Atherothrombotic Strokes in Persons of European Ancestry, According to Study

Our well-powered meta-analyses did not validate previously reported associations between two SNPs (rs12425791 and rs11833579) and stroke.1 This lack of validation is most likely because of a false positive result in the previous meta-analysis. Differences between our predominantly case–control sample and the cohort sample of the original study may also have been factors. Given the power of our meta-analysis, a false negative finding is unlikely. Our results strongly suggest that these SNPs do not confer a substantial, generalizable risk for ischemic stroke.

Supplementary Material

Supplementary Appendix

Footnotes

Individual investigators are listed in the Supplementary Appendix.

Representatives of the consortium (Jonathan Rosand, M.D. [Massachusetts General Hospital, Boston], James F. Meschia, M.D. [Mayo Clinic, Jacksonville, FL], and Andrew B. Singleton, Ph.D. [National Institute on Aging, Bethesda, MD]) assume responsibility for the overall content and integrity of the letter.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

References

1. Ikram MA, Seshadri S, Bis JC, et al. Genomewide association studies of stroke. N Engl J Med. 2009;360:1718–1728. [PMC free article] [PubMed]
2. Adams HP, Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke. 1993;24:35–41. [PubMed]
3. Zeggini E, Ioannidis JP. Meta-analysis in genome-wide association studies. Pharmacogenomics. 2009;10:191–201. [PMC free article] [PubMed]

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

  • Genetic susceptibility to ischemic stroke[Nature reviews. Neurology. ]
    Meschia JF, Worrall BB, Rich SS. Nature reviews. Neurology. 7(7)369-378
  • Bio-repository of DNA in stroke: a study protocol of three ancestral populations[JRSM Cardiovascular Disease. ]
    Cotlarciuc I, Khan MS, Maheshwari A, Yadav S, Khan FY, Al-Hail H, de Silva R, Gorthi SP, Gupta S, Sharma SR, Sylaja PN, Prasad K, Sharma P. JRSM Cardiovascular Disease. 1(4)cvd.2012.012019
  • Stroke-Related Translational Research[Archives of neurology. 2011]
    Caplan LR, Arenillas J, Cramer SC, Joutel A, Lo EH, Meschia J, Savitz S, Tournier-Lasserve E. Archives of neurology. 2011 Sep; 68(9)1110-1123
  • Stroke genetics: prospects for personalized medicine[BMC Medicine. ]
    Markus HS. BMC Medicine. 10113
  • Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies[Lancet Neurology. 2012]
    Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng YC, Fornage M, Ikram MA, Malik R, Bevan S, Thorsteinsdottir U, Nalls MA, Longstreth W, Wiggins KL, Yadav S, Parati EA, DeStefano AL, Worrall BB, Kittner SJ, Khan MS, Reiner AP, Helgadottir A, Achterberg S, Fernandez-Cadenas I, Abboud S, Schmidt R, Walters M, Chen WM, Ringelstein EB, O'Donnell M, Ho WK, Pera J, Lemmens R, Norrving B, Higgins P, Benn M, Sale M, Kuhlenbäumer G, Doney AS, Vicente AM, Delavaran H, Algra A, Davies G, Oliveira SA, Palmer CN, Deary I, Schmidt H, Pandolfo M, Montaner J, Carty C, de Bakker PI, Kostulas K, Ferro JM, van Zuydam NR, Valdimarsson E, Nordestgaard BG, Lindgren A, Thijs V, Slowik A, Saleheen D, Paré G, Berger K, Thorleifsson G, The Australian Stroke Genetics Collaborative, Wellcome Trust Case Control Consortium 2 (WTCCC2), Hofman A, Mosley TH, Mitchell BD, Furie K, Clarke R, Levi C, Seshadri S, Gschwendtner A, Boncoraglio GB, Sharma P, Bis JC, Gretarsdottir S, Psaty BM, Rothwell PM, Rosand J, Meschia JF, Stefansson K, Dichgans M, Markus HS, on behalf of the International Stroke Genetics Consortium. Lancet Neurology. 2012 Nov; 11(11)951-962
See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...